# BPC-157 TB-500 Dosage in the Research Literature (Animal Models, Not Guidance) > BPC-157 TB-500 dosage as reported in studies: animal-model doses by body weight, the non-monotonic Tbeta4 range, reconstitution for research, and why no validated blend dose exists. Cited, not prescriptive. Doses are reported strictly as administered to species in published research — never as a protocol. The blend itself has no validated dose, ratio, or cycling schedule. ## BPC-157 and TB-500 Dosage in the Research Literature BPC-157 TB-500 dosage has no validated figure for the blend. Commercial research-product labeling commonly pairs the two at fixed combined masses per vial — for example, roughly 10 mg + 10 mg, or a 20 mg combined vial — but no peer-reviewed combination dose-finding study exists [4]. What follows is reported strictly as administered to species in studies, never as human guidance. For the BPC-157 component, rodent studies commonly express dose per body weight, frequently around 10 µg/kg and 10 ng/kg [1]; gastric-ulcer cytoprotection has been studied at 400-800 ng/kg in rats. For the TB-500 / thymosin beta-4 component, the animal range is wide — for example, 2-18 mg/kg intraperitoneal in a rat embolic-stroke dose-response study, with the optimal modeled near 3.75 mg/kg and 18 mg/kg giving no benefit, so higher was not better [4]; and 150 µg twice weekly intraperitoneally for six months in the mdx muscular-dystrophy study [4]. Human single-agent reference points exist only for full-length thymosin beta-4, not the blend or the 7-mer: intravenous Tbeta4 was well tolerated to 1,260 mg [6] and to 25 µg/kg single, 5 µg/kg-daily for 10 days in the 2021 first-in-human study [7]. Community "loading then maintenance" blend protocols have no controlled-trial basis. ### How Much BPC-157 and TB-500 Has Been Used in Studies? No validated weekly dose exists for the blend. Animal-model reference points include BPC-157 around 10 µg/kg and 10 ng/kg in rodents [1], and full-length thymosin beta-4 across a wide range in animal studies [4]; these are not human dosing recommendations. The pairing itself has never been dose-found in a controlled study. ## Wolverine Injection: Reconstitution and Research Handling The phrase "wolverine injection" describes a route of administration, not a validated product or dose. Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated [4]. A common research-community practice is to reconstitute the two peptides separately or in a shared vial; whichever is done, product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [4]. The predominant research-community injection routes are subcutaneous and intramuscular, while the underlying rodent efficacy studies for both peptides were largely intraperitoneal [1][4]. None of these routes is supported by a controlled human efficacy trial of the pairing. This is a description of how research material is handled, not a preparation or administration instruction for use. ## Why the dose record cannot become guidance Every figure on this page is an artifact of a study design, not a recommendation. The rodent doses are expressed per body weight in animals dosed intraperitoneally in controlled experiments [1]; the wide Tbeta4 range comes from disease models that bear no fixed relationship to a research-use protocol for a fragment blend, and where the highest dose gave no benefit at all [4]. Translating any of these numbers into a human regimen would require pharmacokinetic, dose-finding, and safety data that do not exist for the pairing — see [BPC-157 and TB-500 half-life](/half-life) for why even the single-constituent pharmacokinetics do not transfer. The safety picture reinforces the point. The combination's safety is unproven, and a specific concern attaches to the TB-500 leg: thymosin beta-4 is implicated in tumor metastasis and angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair could in principle support tumor progression — a concern that compounds when two pro-repair peptides are combined, as noted under the [tumor and angiogenesis safety signal](/faq#safety). A 2026 review of unapproved musculoskeletal peptides records scarce human safety data and the potential for serious harm across this whole class [10]. The dose record is here to be understood, not followed. --- A distilled field-record of the BPC-157 and TB-500 literature — each peptide pressed as its own cited specimen, its 503A access status read first, with no clinic behind the folio and nothing here prescribed or sold.